Evaluation of Surface Modified Live Biotherapeutic Products for Oral Delivery.

ABSTRACT: Live biotherapeutic products (LBPs), including symbiotic and genetically engineered bacteria, are a promising class of emerging therapeutics that are widely investigated both preclinically and clinically for their oral delivery to the gastrointestinal (GI) tract. One emergent delivery strategy involves the direct functionalization of LBP surfaces through noncovalent or covalent modifications to control LBP interactions with the GI microenvironment, thereby improving their viability, attachment, or therapeutic effect. However, unlike other therapeutic modalities, LBPs are living organisms which present two unique challenges for surface modifications: (1) this approach can directly interfere with key LBP biological processes (e.g., colonization, metabolite secretion) and (2) modification can

SUBMITTER: Vargason AM 

PROVIDER: S-EPMC8243403 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature